Skip to main content

Advertisement

Table 1 Profile of major fatty acids, at baseline and with rosiglitazone

From: Peroxisome proliferator-activated receptor gamma modulation and lipogenic response in adipocytes of small-for-gestational age offspring

Fatty Acids Percent of Total (%)
  Control SGA
Fatty Acid Baseline Rosiglitazone Baseline Rosiglitazone
Palmitate 16:0 36.4 ± 1.5 37.9 ± 1.1 37.5 ± 0.7 37.7 ± 2.4
Palmitoleate 16:1n-7 3.4 ± 0.1 3.09 ± 0.04 3.4 ± 0.1 3.3 ± 0.3
Stearate 18:0 22.6 ± 0.9 29.1 ± 0.9* 20.8 ± 0.6 22.4 ± 1.4c
Oleate 18:1n-9 19.7 ± 0.7 17.4 ± 0.4 20.0 ± 0.3 20.1 ± 1.2
Vaccenate 18:1n-7 12.0 ± 0.5 10.4 ± 0.2 13.2 ± 0.3 12.1 ± 0.9
  1. Cp < 0.05 compared with Control receiving the same treatment.
  2. *p < 0.05 compared to the untreated state within the same group.
  3. The fatty acid percentages of total are presented as the mean ± the standard error of the mean (SEM). With rosiglitazone treatment, Controls demonstrated increased stearate abundance.